Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Mon, 22 Jan 2018 17:36:36 EST

Copyright: Copyright: (C) Marketwired
 



Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

Mon, 22 Jan 2018 17:05:00 EST

LAVAL, QUÉBEC--(Marketwired - Jan. 22, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares (the "Offering") have given notice to exercise their over-allotment option by purchasing an additional 766,179 common shares at a price of US$1.01 per share, for additional gross proceeds to Acasti of approximately US$773,000. Closing of the exercise of the over-allotment option occurred on Monday, January 22, 2018.




VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference

Mon, 22 Jan 2018 08:30:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - January 22, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief Executive Officer of VistaGen, will provide an update on the Company's Phase 2 study of AV-101 as an oral new generation adjunctive treatment for Major Depressive Disorder (MDD) and outline key 2018 initiatives at the 14th Annual Noble Capital Markets' Investor Conference - NobleCon14 - to be held at the W Fort Lauderdale hotel in Fort Lauderdale, FL on Monday, January 29th at 4:30 p.m. ET.




Leading Leukemia Experts Join Moleculin's Science Advisory Board

Wed, 17 Jan 2018 08:30:00 EST

HOUSTON, TX--(Marketwired - January 17, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the expansion of its Science Advisory Board to include Drs. Jorge Cortes and Elihu Estey.




Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

Wed, 17 Jan 2018 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the following key additions to its leadership team:




CTD Holdings' European Clinical Trial Adopted by National Institute for Health Research of England

Tue, 16 Jan 2018 08:00:00 EST

Collaboration Will Provide Infrastructure Support to Study




Acasti Pharma Announces Change to Board of Directors

Tue, 16 Jan 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Jan. 16, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Neptune's representatives, Rick Schottenfeld and Katherine Crewe, have resigned from Acasti's Board of Directors.